| Name | Title | Contact Details |
|---|
Dechra Pharmaceuticals PLC is a global leader in veterinary pharmaceuticals, dedicated exclusively to the veterinary market. Founded in 1997, the company has a rich history dating back to 1819. Dechra develops, manufactures, and markets high-quality pharmaceutical products and services aimed at improving animal health and welfare. It operates in 24 countries and distributes products in over 50 countries. The company offers a diverse portfolio of prescription-only veterinary medicines for companion animals and horses, focusing on areas such as endocrinology, dermatology, and critical care. Dechra also provides water-soluble antibiotics, poultry vaccines, and specialized diets. Its services division includes laboratories that support veterinary diagnostics. With a strong emphasis on understanding veterinarians needs, Dechra provides training and scientific resources to enhance animal care.
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.